List of Excipients in Branded Drug UROCIT-K

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Mission Pharmacal Company	UROCIT-K	potassium citrate	0178-0600	CARNAUBA WAX
Mission Pharmacal Company	UROCIT-K	potassium citrate	0178-0600	MAGNESIUM STEARATE
Mission Pharmacal Company	UROCIT-K	potassium citrate	0178-0610	CARNAUBA WAX
Mission Pharmacal Company	UROCIT-K	potassium citrate	0178-0610	MAGNESIUM STEARATE
Physicians Total Care Inc	UROCIT-K	potassium citrate	54868-4779	CARNAUBA WAX

Urocit-K Excipient Strategy and Commercial Opportunities

Last updated: August 29, 2026

Urocit-K is an extended-release potassium citrate product used to manage hypocitraturia and reduce the recurrence of uric acid and calcium kidney stones. Its commercial value rests on reliable potassium delivery, gastrointestinal tolerability, tablet swallowability, and dose flexibility rather than on a complex active pharmaceutical ingredient. The strongest opportunities are generic or authorized-generic substitution, improved extended-release formulations, lower-pill-burden products, and alternative dosage forms that preserve citrate delivery while improving adherence.

What is Urocit-K and how is it formulated?

Urocit-K contains potassium citrate in extended-release tablet form. The product is marketed in 5 mEq, 10 mEq, and 15 mEq strengths, although availability can vary by market and product presentation. The label instructs patients to take the tablets with meals or within 30 minutes after meals and to swallow them whole with water. Crushing, chewing, or sucking the tablets can disrupt the intended release profile and increase local gastrointestinal exposure. (Mission Pharmacal, 2023)

Product characteristic	Urocit-K profile
Active ingredient	Potassium citrate
Therapeutic use	Hypocitraturia, uric acid lithiasis, calcium oxalate stone prevention
Dosage form	Extended-release tablet
Common strengths	5 mEq, 10 mEq, and 15 mEq
Administration	With meals or shortly after meals
Release requirement	Extended release
Key tolerability issue	Gastrointestinal irritation
Key adherence issue	Large tablet size and multiple daily doses
Prescription status	FDA-approved prescription product
Biosimilar relevance	None; Urocit-K is a small-molecule drug

The product label identifies inactive ingredients that support tablet manufacture, matrix formation, lubrication, flow, and physical stability. Public labeling has identified excipient classes including wax-based release-control material, microcrystalline cellulose, magnesium stearate, silicon dioxide, sodium benzoate, and talc. The exact composition and manufacturing process should be confirmed against the current approved labeling and regulatory filings before commercial use. (DailyMed, 2024)

What excipients protect Urocit-K’s extended-release performance?

The core excipient strategy is a hydrophobic matrix that moderates dissolution of the highly water-soluble potassium citrate salt.

Hydrophobic release-control excipients

Carnauba wax or another pharmaceutical-grade wax can reduce water penetration and slow erosion of the tablet matrix. This approach is commercially attractive because it can produce extended release without relying on a coated multiparticulate system. It also permits relatively simple tablet manufacturing.

The main development risks are:

• Release-rate sensitivity to compression force
• Variability caused by particle size and wax distribution
• Food effects
• Dose-dumping risk if the matrix is damaged
• Batch-to-batch dissolution differences

Wax matrices must be evaluated under discriminatory dissolution conditions. Standard compendial testing may not reveal clinically relevant differences between formulations, particularly where the product is intended to release potassium citrate across several hours.

Microcrystalline cellulose

Microcrystalline cellulose can provide compressibility, tablet structure, and matrix support. It is useful for high-load tablets because potassium citrate contributes substantial ionic and crystalline material but does not necessarily provide the mechanical properties required for robust direct compression.

The commercial tradeoff is tablet size. Increasing microcrystalline cellulose may improve hardness and reduce friability, but it can make an already large potassium citrate tablet harder to swallow.

Magnesium stearate

Magnesium stearate supports lubrication and ejection from the tablet press. Excessive use can impair wetting and slow dissolution, especially in hydrophobic extended-release systems. The lubricant concentration and blending time therefore become part of the release-control strategy rather than only a manufacturing parameter.

Silicon dioxide

Colloidal silicon dioxide can improve powder flow and reduce segregation during high-dose blending. This is relevant where the active ingredient represents a large proportion of the tablet mass. Its commercial value is primarily process robustness, not therapeutic differentiation.

Sodium benzoate and talc

These excipients may support processing, stability, or physical characteristics depending on the formulation. Their use must be assessed against patient-specific considerations, including sodium exposure, excipient sensitivity, and regional regulatory requirements.

What formulation patents and intellectual-property barriers affect Urocit-K?

Urocit-K is a small-molecule product, so biosimilar regulation does not apply. The principal competitive pathway is an abbreviated new drug application, or ANDA, for a therapeutically equivalent potassium citrate extended-release product.

The relevant intellectual-property categories are:

IP category	Relevance to Urocit-K competition
Composition patents	Potentially limited where the active ingredient is an established salt
Extended-release matrix patents	Can protect wax systems, polymer matrices, coating structures, or dissolution profiles
Method-of-use patents	Could cover stone-prevention indications, dosing, or patient subgroups
Manufacturing patents	May cover granulation, compression, coating, or controlled-release processing
Trade secrets	May protect excipient ratios, process parameters, and dissolution-control methods
Trademark rights	Protect the Urocit-K name but do not prevent generic potassium citrate products
Regulatory exclusivity	Usually less important for an established product than Orange Book-listed patents

The principal barrier is likely formulation equivalence, not the chemical identity of potassium citrate. An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. Differences in inactive ingredients may be acceptable if they do not affect safety, performance, or bioequivalence. (FDA, 2017)

Current Orange Book status should be checked by product name, strength, and application number before making a launch or litigation decision. Orange Book-listed patents, if any, can create Paragraph IV exposure. A generic applicant may certify that listed patents are invalid, unenforceable, or will not be infringed. The brand holder can then bring patent litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework. (FDA, 2024a)

When does Urocit-K lose exclusivity and what does that mean commercially?

Urocit-K’s active ingredient is long established, and the commercial market is compatible with generic competition. The key timing issue is not loss of basic active-ingredient exclusivity but the status of any current listed formulation or method-of-use patents and the availability of approved therapeutically equivalent products.

Commercial entry can occur through several scenarios:

1. A fully substitutable generic extended-release tablet enters after resolving applicable patent certifications.
2. An authorized generic is launched through a brand-controlled licensing or supply arrangement.
3. A nonidentical potassium citrate dosage form competes through a separate NDA or 505(b)(2) pathway.
4. A reformulated product obtains differentiation through adherence, dose flexibility, or tolerability.

Price erosion would likely be strongest for a therapeutically equivalent tablet. Differentiated products can preserve margin if they solve a clear administration problem, such as tablet burden or swallowing difficulty.

What excipient strategies could create new commercial products?

Smaller high-load tablets

A smaller tablet could improve adherence, but potassium citrate creates a high active-load challenge. Opportunities include:

• Higher-density granulation
• Optimized particle engineering
• More efficient compression
• Reduced excipient burden
• Bilayer or multilayer tablet design
• Mini-tablet multiparticulates placed in a capsule

The critical constraint is maintaining extended release without increasing gastrointestinal irritation or compromising dose uniformity.

Multiparticulate extended-release systems

Pellets or mini-tablets can distribute potassium citrate across the gastrointestinal tract and may offer improved release control. A capsule containing coated multiparticulates could be easier to swallow than a large monolithic tablet. The technology also permits strength flexibility by changing fill weight or pellet count.

Potential drawbacks include higher manufacturing cost, coating complexity, moisture sensitivity, and the need to demonstrate that opening the capsule does not alter performance.

Oral powder or sachet products

A powder for dispersion could address patients who cannot swallow tablets. The commercial challenge is controlling immediate potassium exposure and maintaining acceptable taste. Potassium salts often have a salty, bitter, or metallic taste. Taste-masking excipients, buffering agents, sweeteners, and flavor systems would be central to product acceptance.

A powder product would also require careful instructions regarding water volume, mixing, meal timing, and complete dose transfer.

Liquid and suspension formulations

A liquid potassium citrate product could serve pediatric, geriatric, and dysphagia populations. It would need:

• Chemical and physical stability
• Accurate dosing across measuring devices
• Preservative control
• Palatable flavoring
• Protection against sedimentation or crystallization
• Clear instructions for storage and shaking

A liquid dosage form may compete less directly with Urocit-K tablets and could qualify as a differentiated product rather than a conventional generic.

Low-sodium and excipient-controlled formulations

Patients managing hypertension, renal disease, or cardiovascular risk may value a product with carefully controlled sodium exposure. A formulation marketed as sodium-conscious must distinguish sodium introduced by excipients from the potassium citrate active ingredient and must comply with labeling rules.

Other potential differentiation areas include sugar-free, dye-free, gluten-free, vegan-compatible, and allergen-controlled formulations. These claims require documentary control of the full supply chain.

How strong is the Urocit-K formulation estate?

The formulation estate is likely strongest where it protects a reproducible extended-release profile that is difficult to duplicate without infringing process or matrix claims. It is weaker for routine excipients used at conventional levels, because many excipient combinations are available to competitors.

Protection area	Relative commercial strength
Potassium citrate active ingredient	Low, because it is established and widely available
Conventional tablet excipients	Low to moderate
Specific wax-matrix architecture	Moderate to high, depending on claim scope
Dissolution profile	Moderate, if linked to enforceable formulation claims
Tablet size and compression process	Moderate
Taste-masked liquid or powder	Moderate to high for differentiated products
Manufacturing know-how	Potentially high as a trade secret
Method of use	Variable and dependent on current patent listings

A formulation patent is more defensible when it claims a specific excipient ratio, processing sequence, release profile, or performance result rather than a broad list of conventional ingredients. Freedom-to-operate analysis should cover composition, process, dissolution, and dosage-form claims in the United States and major commercial jurisdictions.

Which companies are challenging or competing with Urocit-K?

Competition comes from three groups:

Generic manufacturers

Generic companies can target potassium citrate extended-release tablets through ANDA filings. Their priorities are low-cost manufacturing, therapeutic equivalence, reliable dissolution, and pharmacy substitution.

Branded alternative products

Other prescription potassium citrate products may compete through different strengths, dosage forms, or release technologies. Brand competition is more likely to focus on adherence, patient support, and distribution than on active-ingredient differentiation.

Compounded and dietary-supplement products

Compounded potassium citrate liquids and over-the-counter citrate supplements may address adjacent demand but do not necessarily provide equivalent extended-release performance, regulatory status, or clinical evidence. They may compete in cash-pay or lower-acuity segments while remaining unsuitable substitutes for prescription products.

What FDA regulatory pathway applies to new Urocit-K products?

A conventional generic extended-release tablet would generally use the ANDA pathway. The applicant must establish pharmaceutical equivalence and bioequivalence and satisfy requirements for chemistry, manufacturing, controls, labeling, and product performance.

A materially different product, such as a liquid, powder, or novel multiparticulate system, may require an NDA or 505(b)(2) application. The regulatory burden rises when the product changes release characteristics, dosing instructions, excipient exposure, or the patient population.

Key development packages include:

• Comparative dissolution testing
• Stability under accelerated and long-term conditions
• Dose-uniformity and assay testing
• Impurity and degradation-product control
• In vitro alcohol-dose-dumping assessment where relevant
• Food-effect assessment
• Bioequivalence studies
• Container-closure compatibility
• Excipient safety justification

The FDA’s modified-release guidance emphasizes product-specific dissolution and pharmacokinetic evidence. (FDA, 2003)

What generic launch risks exist for Urocit-K?

The primary launch risks are technical and commercial:

• Failure to match the reference product’s release profile
• Tablet size that reduces patient acceptance
• Inadequate control of potassium exposure
• Food-dependent pharmacokinetic variability
• Manufacturing scale-up problems
• Patent litigation following a Paragraph IV certification
• Pharmacy resistance if substitution economics are weak
• Limited market size relative to development cost
• Recall risk from dose-uniformity or dissolution failures

Potassium-containing products also require strong controls because excessive exposure can cause clinically serious hyperkalemia in susceptible patients. Labeling, risk management, and patient selection remain important commercial considerations.

How does Urocit-K compare with potential reformulations?

Attribute	Urocit-K-type tablet	Smaller tablet	Multiparticulate capsule	Liquid or powder
Generic substitution potential	High	Moderate	Low to moderate	Low
Development complexity	Moderate	Moderate to high	High	High
Swallowability	Limited	Improved	Improved	Highest
Release-control flexibility	Moderate	Moderate	High	Variable
Taste risk	Low	Low	Low	High
Manufacturing cost	Low to moderate	Moderate	High	Moderate to high
Differentiation potential	Low	Moderate	High	High
Likely regulatory pathway	ANDA	ANDA or 505(b)(2)	505(b)(2) or ANDA, depending on equivalence	NDA or 505(b)(2)

Key Takeaways

• Urocit-K’s core formulation value is extended-release control for a high-load potassium citrate tablet.
• Conventional excipients are unlikely to create durable exclusivity by themselves.
• Wax-matrix architecture, dissolution performance, compression parameters, and manufacturing know-how are the more relevant protection areas.
• Generic competition is the main commercial threat; biosimilar competition does not apply.
• Smaller tablets, multiparticulate capsules, liquids, and taste-masked powders offer the clearest product-development opportunities.
• An ANDA is the likely route for a therapeutically equivalent extended-release tablet.
• A differentiated liquid, powder, or multiparticulate product may require an NDA or 505(b)(2) application.
• Current Orange Book listings and Paragraph IV certifications should be reviewed before making a launch, licensing, or litigation decision.

FAQs about Urocit-K excipients and commercial opportunities

Can Urocit-K tablets be crushed or split?

The product labeling instructs patients to swallow the extended-release tablets whole. Crushing, chewing, or sucking the tablets can alter release and increase gastrointestinal exposure.

Is potassium citrate an excipient in Urocit-K?

No. Potassium citrate is the active pharmaceutical ingredient. Excipients support compression, release control, flow, lubrication, stability, and patient acceptability.

Could a potassium citrate liquid replace Urocit-K tablets?

A liquid could serve patients with swallowing limitations, but it would not automatically be therapeutically equivalent to the extended-release tablet. It would require separate formulation, stability, dosing, and regulatory evaluation.

Are potassium citrate supplements equivalent to Urocit-K?

Not necessarily. Supplements may differ in potassium dose, citrate content, release profile, quality controls, and clinical labeling. They should not be treated as automatic substitutes for a prescription extended-release product.

What is the most attractive commercial reformulation opportunity?

A smaller, easier-to-swallow extended-release product has the broadest potential market. Multiparticulate capsules and taste-masked liquids offer greater differentiation but carry higher development and manufacturing costs.

References

1. DailyMed. (2024). Urocit-K potassium citrate extended-release tablets: Prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2003). Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products: General considerations. FDA.

3. U.S. Food and Drug Administration. (2017). FDA’s guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

4. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

5. Mission Pharmacal Company. (2023). Urocit-K potassium citrate extended-release tablets: Full prescribing information. Mission Pharmacal Company.